WO2006042928A1 - Composition for preventing or treating stress, especially chronic and permanent bursts of stress - Google Patents

Composition for preventing or treating stress, especially chronic and permanent bursts of stress Download PDF

Info

Publication number
WO2006042928A1
WO2006042928A1 PCT/FR2005/002463 FR2005002463W WO2006042928A1 WO 2006042928 A1 WO2006042928 A1 WO 2006042928A1 FR 2005002463 W FR2005002463 W FR 2005002463W WO 2006042928 A1 WO2006042928 A1 WO 2006042928A1
Authority
WO
WIPO (PCT)
Prior art keywords
stress
extract
melissa
composition according
composition
Prior art date
Application number
PCT/FR2005/002463
Other languages
French (fr)
Inventor
Serge Sonie
Denis Marin
Original Assignee
Persee Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Persee Medica filed Critical Persee Medica
Publication of WO2006042928A1 publication Critical patent/WO2006042928A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention relates to the field of the prevention and / or treatment of stress and more particularly to a composition for preventing or treating chronic and permanent stress flushes.
  • stress is defined as the non-specific response of the body to any external demand, mainly in the form of physical or mental aggression. Stress is mainly characterized by signs and psychic disorders (intellectual overwork, sleep disorders, anxiety, anxiety), somatic (headaches and diffuse pain, dermatitis and minor skin conditions, low resistance to infections) and behavioral ( excessive sweating, redness of the face, difficulty in expressing oneself, disturbances of memory).
  • signs and psychic disorders intellectual overwork, sleep disorders, anxiety, anxiety
  • somatic headaches and diffuse pain, dermatitis and minor skin conditions, low resistance to infections
  • behavioral excessive sweating, redness of the face, difficulty in expressing oneself, disturbances of memory.
  • a first phase corresponds to an alarm reaction, characterized by an acceleration of the heart rate with short and rapid breathing, muscle tension, dryness of the throat, redness in the neck or face, excessive sweating, difficulties in expressing oneself and thinking serenely, difficulties in concentrating. These signs are transient and are commonly referred to as "stress flushes".
  • the resistance stage (second phase) is characterized by an adaptation of the body and organs to resist aggression over a short or medium period.
  • the mechanisms implemented by the body can be adapted, or on the contrary inappropriate and disproportionate to a normal and adequate response to the given situation.
  • the intellectual performances decrease, the patient depresses, becomes extremely nervous and aggressive, suffers from sleep disorders, memory loss, ....
  • cortisol another hormone, called cortisol, which intervenes.
  • hypothalamic cortisol receptors become less sensitive to reactive inhibition with, as a result, an increase in cortisol production.
  • excessive production of cortisol is associated with a large number of metabolic disorders of the hypothalamic-pituitary-adrenal axis including insulin resistance, obesity, increased blood pressure, immunosuppression or the disruption of wound healing.
  • an excessive and prolonged elevation of cortisol leads to signs and symptoms that are those of a permanent state of stress, such as a lasting tension, a repeated emotivity, disorders of the hypersensitivity and an irritation.
  • This second stage which mainly involves cortisol, is assimilated to chronic burst of stress.
  • melissa (Melissa officinalis) is known, whose characteristic is to present sedative properties. Melissa is traditionally used in the symptomatic treatment of neurotonic states (minor sleep disorders). Chronic stress is characterized by the appearance and persistence over long periods of neurotonic disorders, especially difficulty falling asleep and a decrease in the quality of sleep, it makes perfect sense to incorporate lemon balm into a preparation intended to fight against chronic stress.
  • melissa extracts essential oil, hydro ⁇ alcoholic extract, supercritical CO 2 extracts
  • preparations based on total melissa powder Several studies have been conducted with melissa extracts (essential oil, hydro ⁇ alcoholic extract, supercritical CO 2 extracts) or preparations based on total melissa powder.
  • the first issue concerns the rapid evaporation of the substances responsible for the sedative activity on the stress hormone. Indeed, citral, neral and citronellal are extremely volatile terpenes. Melissa powder preparations, and extracts whose hydro-alcoholic extract (which contains the three compounds) must be protected from light, air and moisture, so that avoid their evaporation.
  • the second problem concerns a weak absorption of the non-water-soluble compounds by the gastrointestinal tract.
  • citral, neral, citronellal and some of the other compounds mentioned above are highly hydrophobic substances, and therefore are poorly absorbed by the gastrointestinal mucosa.
  • the oral route which is the preferred route of administration for chronic treatments, has indeed a major disadvantage for many molecules of low aqueous bioavailability.
  • dissolution in the digestive environment is therefore a limiting step of the absorption process.
  • the presence in lemon balm extracts of non-water-soluble compounds that are poorly absorbed by the gastrointestinal tract thus constitutes another drawback in the use of lemon balm.
  • the present invention intends to overcome the disadvantages of the prior art by providing a composition for increasing the anti-stress action.
  • melissa extracts by an increase in its bioavailability.
  • the present invention therefore aims to provide a composition having improved dissolution in the digestive environment.
  • the present invention also aims to propose a composition having a limited evaporation of volatile derivatives responsible for the sedative activity.
  • the present invention is of the type described above and is remarkable, in its broadest sense, in that the composition comprises a melissa extract (Melissa officinalis) and a substance Sl allowing the dissolution in an environment digestive complex compounds contained in the extract of melissa, responsible for a sedative activity and acting on stress mediators.
  • a melissa extract Melissa officinalis
  • Sl substance Sl allowing the dissolution in an environment digestive complex compounds contained in the extract of melissa, responsible for a sedative activity and acting on stress mediators.
  • the inventors have found that the compounds used in the composition according to the invention have complementary modes of action thus offering a synergy for a more effective action.
  • stress mediators we mean the main hormones responsible for stress, as well as any other chemical compound involved in stress.
  • the composition further comprises a substance S2 for reducing the evaporation of said compounds.
  • the substance (s) added to the melissa extracts (Sl and / or S2) comprise active agents acting directly on the stress.
  • This property of the substance (s) added to the extracts of the lemon balm thus makes it possible not only to limit the addition of too many ingredients to the final product, but also to reduce any risk of impossibility of industrial implementation of the invention (for example, too many tablets to be swallowed every day because of the final amount of the mixture).
  • the substances S1 and S2 are characterized by a single substance, phosphatidylserine.
  • phosphatidylserine makes it possible, when used in conjunction with a lemon balm extract: to promote the absorption of hydrophobic substances contained in the lemon balm extract by improving its dissolution in a digestive environment; to reduce the evaporation of the volatile compounds of the lemon balm extracts by forming a protective layer within the matrix of the tablet.
  • phosphatidylserine is of additional interest when combined with lemon balm extract as it has cortisol-lowering properties, thus acting directly on the chronic stress hormone .
  • Phosphatidylserine also has indirect properties on certain symptoms of stress such as memory problems. She is widely recommended as a complementary treatment of Alzheimer's disease, and references to the use of this compound in the world of stress are quite rare.
  • composition according to the invention further comprises one or more pharmacological excipients compatible and adapted to the mode of administration. Because of the regulation of food supplements, this composition will be in the form of tablets to be administered orally.
  • the composition according to the invention comprises an amount of melissa extract and phosphatidylserine allowing a daily intake of one or more doses of 50 to 500 g of phosphatidylserine and 100 to 1000 mg of melissa extract, the amount of extract melissa and phosphatidylserine being preferably chosen to allow a daily intake of one or more doses of 100 mg of phosphatidylserine and 300 mg of melissa extract.
  • This formulation thus makes it possible to meet the expectations regarding optimal use of the quantities of active ingredients to be incorporated in a tablet, the preferred final formulation being the daily intake of two tablets.

Abstract

The invention relates to a composition for preventing or treating stress, especially chronic bursts of stress. Said composition is characterised in that it comprises a melissa extract (Melissa officinalis) and a substance Sl acting on stress mediators and enabling the dissolution, in a digestive environment, of compounds which are contained in the melissa extract and have a sedative activity. The inventive composition is also characterised in that it comprises a substance S2 for reducing the evaporation of said compounds.

Description

COMPOSITION POUR PREVENIR OU TRAITER LE STRESS, NOTAMMENT LES BOUFFEES DE STRESS CHRONIQUE ET PERMANENT COMPOSITION FOR PREVENTING OR TREATING STRESS, INCLUDING CHRONIC AND PERMANENT STRESS BURNS
La présente invention se rapporte au domaine de la prévention et/ou du traitement du stress et plus particulièrement à une composition permettant de prévenir ou de traiter les bouffées de stress chronique et permanent.The present invention relates to the field of the prevention and / or treatment of stress and more particularly to a composition for preventing or treating chronic and permanent stress flushes.
De manière générale, le stress est défini comme la réponse non spécifique de l'organisme à toute demande extérieure, principalement sous forme d'une agression physique ou psychique. Le stress est caractérisé principalement par des signes et des troubles psychiques (surmenage intellectuel, troubles du sommeil, anxiété, angoisse), somatiques (maux de tête et douleurs diffuses, dermites et affections mineures de la peau, faible résistance aux infections) et comportementaux (transpiration excessive, rougeurs de la face, difficulté à s'exprimer, troubles de la mémoire).In general, stress is defined as the non-specific response of the body to any external demand, mainly in the form of physical or mental aggression. Stress is mainly characterized by signs and psychic disorders (intellectual overwork, sleep disorders, anxiety, anxiety), somatic (headaches and diffuse pain, dermatitis and minor skin conditions, low resistance to infections) and behavioral ( excessive sweating, redness of the face, difficulty in expressing oneself, disturbances of memory).
La réaction de stress se déroule en trois phases. Une première phase correspond à une réaction d'alarme, caractérisée par une accélération du rythme cardiaque avec une respiration courte et rapide, une tension musculaire, une sécheresse de la gorge, des rougeurs au niveau du cou ou de la face, une transpiration excessive, des difficultés à s'exprimer et à réfléchir sereinement, des difficultés à se concentrer. Ces signes sont passagers et sont communément appelés "bouffées de stress" .The stress reaction takes place in three phases. A first phase corresponds to an alarm reaction, characterized by an acceleration of the heart rate with short and rapid breathing, muscle tension, dryness of the throat, redness in the neck or face, excessive sweating, difficulties in expressing oneself and thinking serenely, difficulties in concentrating. These signs are transient and are commonly referred to as "stress flushes".
Le stade de résistance (deuxième phase) se caractérise par une adaptation du corps et des organes pour résister à l'agression sur une période de courte ou moyenne durée. Les mécanismes mis en œuvre par le corps peuvent être adaptés, ou au contraire inadaptés et disproportionnés par rapport à une réponse normale et adéquate qu'il faudrait apporter à la situation donnée. En cas d'inadaptation prolongée, les performances intellectuelles diminuent, le patient déprime, devient extrêmement nerveux et agressif, souffre de troubles du sommeil, de pertes de mémoire, ....The resistance stage (second phase) is characterized by an adaptation of the body and organs to resist aggression over a short or medium period. The mechanisms implemented by the body can be adapted, or on the contrary inappropriate and disproportionate to a normal and adequate response to the given situation. In case of prolonged maladjustment, the intellectual performances decrease, the patient depresses, becomes extremely nervous and aggressive, suffers from sleep disorders, memory loss, ....
Lorsque le sujet atteint le stade d'épuisement (troisième phase du stress), il présente des signes physiques caractéristiques tels qu'une tension musculaire très forte, accompagnée de maux de tête et de migraines fréquentes, un transit intestinal perturbé (spasmes et douleurs), ou l'apparition d'un ulcère.When the subject reaches the stage of exhaustion (third phase of the stress), it presents characteristic physical signs such as a very strong muscular tension, accompanied with frequent headaches and migraines, a disturbed intestinal transit (spasms and pains) , or the appearance of an ulcer.
Selon l'environnement du sujet et sa capacité à s'adapter aux contraintes qu'il subit, mais également selon la durée des phases de stress, on distingue deux types de stress : le stress aigu et le stress chronique ou permanent.Depending on the subject's environment and his ability to adapt to the stresses that he undergoes, but also according to the duration of the stress phases, there are two types of stress: acute stress and chronic or permanent stress.
Lorsque le sujet est jeune et en bonne santé, sa capacité a s'adapter est forte, et le stress se traduit alors par des bouffées de stress aigu. En revanche, lorsque le sujet n'a plus la capacité de s'adapter, où que cette dernière est réduite, le retour à la normalité est plus lent ou inexistant, les bouffées de stress deviennent plus longues en durée et l'on assiste à l'installation de bouffées de stress chronique ou permanent.When the subject is young and healthy, his ability to adapt is strong, and the stress is then reflected by flashes of acute stress. On the other hand, when the subject no longer has the capacity to adapt, where the latter is reduced, the return to normality is slower or non-existent, the stress puffs become longer in duration and we observe the installation of chronic or permanent stress flushes.
II est connu que, face à une agression extérieure, l'organisme active une réaction hormonale et libère de l'adrénaline, de la noradrénaline et du cortisol. Ces hormones expédient le sang du centre du corps vers les muscles et les membres pour préparer l'organisme à faire face à une éventuelle attaque. Des réponses physiologiques complémentaires assurent une réaction rapide à la menace : les pupilles se dilatent, la conscience s'intensifie, le pouls s'accélère, il y a transpiration et sudation du sujet qui ressent des palpitations. Cette première étape fait intervenir principalement l'adrénaline et est assimilée aux bouffées de stress aigu.It is known that, in the face of external aggression, the body activates a hormonal reaction and releases adrenaline, norepinephrine and cortisol. These hormones send the blood from the center of the body to the muscles and limbs to prepare the body to cope with a possible attack. Additional physiological responses ensure a rapid response to the threat: the pupils dilate, the consciousness intensifies, the pulse accelerates, there is perspiration and sweating of the subject who feels palpitations. This first step involves mainly adrenaline and is assimilated to acute stress flushes.
Cependant, en situation de stress prolongéHowever, in a situation of prolonged stress
(bouffées de stress chronique), c'est une autre hormone, dénommée cortisol, qui intervient. Au cours de cette étape, les récepteurs hypothalamiques au cortisol deviennent moins sensibles à l'inhibition réactive avec, pour résultat, une augmentation de la production de cortisol. Or, une production excessive de cortisol est associée à un grand nombre de désordres métaboliques de l'axe hypothalamo-hypophyso-surénalien incluant 1'insulino-résistance, l'obésité, l'augmentation de la pression sanguine, l'immuno-suppression ou la perturbation de la guérison des blessures. En fait, une élévation excessive et prolongée de cortisol conduit à des signes et symptômes qui sont ceux d'un état permanent de stress, tels qu'une tension durable, une émotivité répétée, des troubles de l'hypersensibilité et une irritation. Cette seconde étape qui fait intervenir principalement le cortisol et est assimilée à des bouffées de stress chroniques.(flushes of chronic stress), it is another hormone, called cortisol, which intervenes. During this step, hypothalamic cortisol receptors become less sensitive to reactive inhibition with, as a result, an increase in cortisol production. However, excessive production of cortisol is associated with a large number of metabolic disorders of the hypothalamic-pituitary-adrenal axis including insulin resistance, obesity, increased blood pressure, immunosuppression or the disruption of wound healing. In fact, an excessive and prolonged elevation of cortisol leads to signs and symptoms that are those of a permanent state of stress, such as a lasting tension, a repeated emotivity, disorders of the hypersensitivity and an irritation. This second stage, which mainly involves cortisol, is assimilated to chronic burst of stress.
L'art antérieur connaît déjà un certain nombre de plantes utilisées dans des compositions destinées à lutter contre le stress chronique, ou tout du moins à en limiter les répercussions. En particulier, on connaît la mélisse (Melissa officinalis) , dont la caractéristique est de présenter des propriétés sédatives. La mélisse est traditionnellement utilisée dans le traitement symptomatique des états neurotoniques (troubles mineurs du sommeil). Le stress chronique étant caractérisé par l'apparition et la persistance sur de longues périodes de troubles neurotoniques, en particulier des difficultés d'endormissement et une diminution de la qualité du sommeil, il est tout à fait logique d'incorporer la mélisse dans une préparation destinée à lutter contre le stress chronique.The prior art already knows a certain number of plants used in compositions intended to combat chronic stress, or at least to limit its effects. In particular, melissa (Melissa officinalis) is known, whose characteristic is to present sedative properties. Melissa is traditionally used in the symptomatic treatment of neurotonic states (minor sleep disorders). Chronic stress is characterized by the appearance and persistence over long periods of neurotonic disorders, especially difficulty falling asleep and a decrease in the quality of sleep, it makes perfect sense to incorporate lemon balm into a preparation intended to fight against chronic stress.
Plusieurs études ont été menées avec des extraits de mélisse (huile essentielle, extrait hydro¬ alcoolique, extraits au CO2 supercritique) ou des préparations à base de poudre totale de mélisse.Several studies have been conducted with melissa extracts (essential oil, hydro¬ alcoholic extract, supercritical CO 2 extracts) or preparations based on total melissa powder.
Ces expérimentations montrent que les substances responsables de l'activité sédative sont contenues dans l'huile essentielle de la plante, dans l'extrait hydro-alcoolique et dans la poudre de mélisse, et sont principalement le citral, le néral et le citronellal. D'autres composés sont également présents tels que l'acétate de géranyle, le -caryophyllène et son oxyde, le germacrène D et plusieurs autres composés d'origine terpénique, l'acide rosmarinique, des triterpènes, les flavonoïdes et les acides malitriques pour n'en citer que quelques-uns. Il est possible que certains des composés précédemment cités présentent des propriétés sédatives.These experiments show that the substances responsible for the sedative activity are contained in the essential oil of the plant, in the hydroalcoholic extract and in the melissa powder, and are mainly citral, neral and citronellal. Other compounds are also present such as geranyl acetate, -caryophyllene and its oxide, germacrene D and several other compounds of terpene origin, rosmarinic acid, triterpenes, flavonoids and malitric acids for n quote only a few. It is possible that some of the above-mentioned compounds have sedative properties.
Cependant, l'utilisation d'extraits de mélisse ou de poudre de mélisse pour agir sur l'hormone responsable du stress chronique présente deux problématiques majeures liées aux actifs présents.However, the use of lemon balm extracts or melissa powder to act on the hormone responsible for chronic stress presents two major issues related to current assets.
La première problématique concerne l'évaporation rapide des substances responsables de l'activité sédative sur l'hormone de stress. En effet, le citral, le néral et le citronellal sont des terpènes extrêmement volatils. Les préparations à base de poudre de mélisse, et les extraits dont l'extrait hydro-alcoolique (qui contient les trois composés) doivent donc être placés à l'abri de la lumière, de l'air et de l'humidité, afin d'éviter leur évaporation avancée.The first issue concerns the rapid evaporation of the substances responsible for the sedative activity on the stress hormone. Indeed, citral, neral and citronellal are extremely volatile terpenes. Melissa powder preparations, and extracts whose hydro-alcoholic extract (which contains the three compounds) must be protected from light, air and moisture, so that avoid their evaporation.
La seconde problématique concerne une faible absorption des composés non hydrosolubles par le tractus gastro-intestinal. En effet, le citral, le néral, le citronellal et certains des autres composés précédemment cités constituent des substances fortement hydrophobes, et de ce fait sont faiblement absorbés par la muqueuse gastro-intestinale. La voie orale, qui constitue la voie d'administration préférentielle pour les traitements chroniques, présente en effet un inconvénient majeur pour de nombreuses molécules de faible biodisponibilité aqueuse. Pour cette classe de composés, la dissolution dans l'environnement digestif constitue donc une étape limitante du processus d'absorption. La présence dans les extraits de mélisse de composés non hydrosolubles, faiblement absorbés par le tractus gastro-intestinal constitue ainsi un autre inconvénient dans l'utilisation de la mélisse.The second problem concerns a weak absorption of the non-water-soluble compounds by the gastrointestinal tract. Indeed, citral, neral, citronellal and some of the other compounds mentioned above are highly hydrophobic substances, and therefore are poorly absorbed by the gastrointestinal mucosa. The oral route, which is the preferred route of administration for chronic treatments, has indeed a major disadvantage for many molecules of low aqueous bioavailability. For this class of compounds, dissolution in the digestive environment is therefore a limiting step of the absorption process. The presence in lemon balm extracts of non-water-soluble compounds that are poorly absorbed by the gastrointestinal tract thus constitutes another drawback in the use of lemon balm.
La présente invention entend remédier aux inconvénients de l'art antérieur en proposant une composition permettant d'augmenter l'action anti-stress des extraits de mélisse par une augmentation de sa biodisponibilité.The present invention intends to overcome the disadvantages of the prior art by providing a composition for increasing the anti-stress action. melissa extracts by an increase in its bioavailability.
La présente invention a donc pour but de proposer une composition présentant une dissolution améliorée dans l'environnement digestif.The present invention therefore aims to provide a composition having improved dissolution in the digestive environment.
La présente invention a également pour but de proposer une composition présentant une évaporation limitée des dérivés volatils responsables de l'activité sédative.The present invention also aims to propose a composition having a limited evaporation of volatile derivatives responsible for the sedative activity.
Pour ce faire, la présente invention est du type décrit ci-dessus et elle est remarquable, dans son acception la plus large, en ce que la composition comprend un extrait de mélisse (Melissa officinalis) et une substance Sl permettant la dissolution dans un environnement digestif des composés contenus dans l'extrait de mélisse, responsables d'une activité sédative et agissant sur les médiateurs du stress.To do this, the present invention is of the type described above and is remarkable, in its broadest sense, in that the composition comprises a melissa extract (Melissa officinalis) and a substance Sl allowing the dissolution in an environment digestive complex compounds contained in the extract of melissa, responsible for a sedative activity and acting on stress mediators.
De manière surprenante, les inventeurs ont constaté que les composés entrant dans la composition selon l'invention, présentent des modes d'action complémentaires offrant ainsi une synergie pour une action plus efficace.Surprisingly, the inventors have found that the compounds used in the composition according to the invention have complementary modes of action thus offering a synergy for a more effective action.
Par médiateurs de stress, on entend les principales hormones responsables du stress, ainsi que tout autre composé chimique impliqué dans le stress.By stress mediators, we mean the main hormones responsible for stress, as well as any other chemical compound involved in stress.
Avantageusement, la composition comprend en outre une substance S2 permettant de diminuer l'évaporation desdits composés. Avantageusement, la ou les substances (s) additionnée(s) aux extraits de mélisse (Sl et/ou S2) comprend des actifs agissant directement sur le stress.Advantageously, the composition further comprises a substance S2 for reducing the evaporation of said compounds. Advantageously, the substance (s) added to the melissa extracts (Sl and / or S2) comprise active agents acting directly on the stress.
Cette propriété de la ou des substance(s) additionnée(s) aux extraits de la mélisse permet ainsi non seulement de limiter l'ajout d'un trop grand nombre d'ingrédients dans le produit final, mais également de réduire tout risque d'impossibilité de mise en œuvre industrielle de l'invention (par exemple, trop de comprimés à avaler chaque jour en raison de la quantité finale du mélange).This property of the substance (s) added to the extracts of the lemon balm thus makes it possible not only to limit the addition of too many ingredients to the final product, but also to reduce any risk of impossibility of industrial implementation of the invention (for example, too many tablets to be swallowed every day because of the final amount of the mixture).
Dans un mode de réalisation préféré de l'invention, les substances Sl et S2 sont caractérisées par une seule et même substance, la phosphatidylsérine.In a preferred embodiment of the invention, the substances S1 and S2 are characterized by a single substance, phosphatidylserine.
En effet, de manière surprenante, la phosphatidylsérine permet, lorsqu'il est utilisé conjointement avec un extrait de mélisse : de favoriser l'absorption de substances hydrophobes contenues dans l'extrait de mélisse en améliorant sa dissolution dans un milieu digestif ; de diminuer l'évaporation des composés volatils des extraits de mélisse en formant une couche protectrice à l'intérieur de la matrice du comprimé.Surprisingly, phosphatidylserine makes it possible, when used in conjunction with a lemon balm extract: to promote the absorption of hydrophobic substances contained in the lemon balm extract by improving its dissolution in a digestive environment; to reduce the evaporation of the volatile compounds of the lemon balm extracts by forming a protective layer within the matrix of the tablet.
Par ailleurs, l'utilisation de la phosphatidylsérine offre un intérêt supplémentaire lorsqu'il est combiné avec l'extrait de la mélisse dans la mesure où il présente des propriétés de diminution du cortisol, agissant ainsi de manière directe sur l'hormone du stress chronique.In addition, the use of phosphatidylserine is of additional interest when combined with lemon balm extract as it has cortisol-lowering properties, thus acting directly on the chronic stress hormone .
La phosphatidylsérine possède également des propriétés indirectes sur certains symptômes du stress tels que les troubles de mémoire. Elle est largement préconisée en tant que traitement complémentaire de la maladie d'Alzheimer, et les références de l'utilisation de ce composé dans l'univers du stress sont assez rares.Phosphatidylserine also has indirect properties on certain symptoms of stress such as memory problems. She is widely recommended as a complementary treatment of Alzheimer's disease, and references to the use of this compound in the world of stress are quite rare.
Avantageusement, la composition selon l'invention comprend en outre un ou plusieurs excipients pharmacologiques compatible(s) et adapté(s) au mode d'administration. Du fait de la réglementation des compléments alimentaires, cette composition se présentera sous forme de comprimés à administrer par voie orale.Advantageously, the composition according to the invention further comprises one or more pharmacological excipients compatible and adapted to the mode of administration. Because of the regulation of food supplements, this composition will be in the form of tablets to be administered orally.
Avantageusement, la composition selon l'invention comprend une quantité d'extrait de mélisse et de phosphatidylsérine permettant un apport journalier en une ou plusieurs prises de 50 à 500g de phosphatidylsérine et 100 à 1000 mg d'extrait de mélisse, la quantité d'extrait de mélisse et de phosphatidylsérine étant de préférence choisie pour permettre un apport journalier en une ou plusieurs prises de 100 mg de phosphatidylsérine et 300 mg d'extrait de mélisse.Advantageously, the composition according to the invention comprises an amount of melissa extract and phosphatidylserine allowing a daily intake of one or more doses of 50 to 500 g of phosphatidylserine and 100 to 1000 mg of melissa extract, the amount of extract melissa and phosphatidylserine being preferably chosen to allow a daily intake of one or more doses of 100 mg of phosphatidylserine and 300 mg of melissa extract.
Cette formulation permet ainsi de répondre aux attentes en matière d'utilisation optimale des quantités d'actifs à incorporer dans un comprimé, la formulation finale préférée étant la prise journalière de deux comprimés.This formulation thus makes it possible to meet the expectations regarding optimal use of the quantities of active ingredients to be incorporated in a tablet, the preferred final formulation being the daily intake of two tablets.
L'invention est décrite dans ce qui précède à titre d'exemple. Il est entendu que l'homme du métier est à même de réaliser différentes variantes de l'invention sans pour autant sortir du cadre du brevet. The invention is described in the foregoing by way of example. It is understood that the skilled person is able to realize different variants of the invention without departing from the scope of the patent.

Claims

REVENDICATIONS
1) Composition pour prévenir ou traiter le stress, notamment les bouffées de stress chronique, caractérisée en ce qu'elle comprend un extrait de mélisse (Melissa officinalis) et une substance Sl permettant la dissolution dans un environnement digestif des composés contenus dans l'extrait de mélisse, responsables d'une activité sédative et agissant sur les médiateurs du stress.1) Composition for preventing or treating stress, in particular flushes of chronic stress, characterized in that it comprises an extract of melissa (Melissa officinalis) and a substance Sl allowing the dissolution in a digestive environment of the compounds contained in the extract of melissa, responsible for a sedative activity and acting on the mediators of stress.
2) Composition selon la revendication 1, caractérisé en ce qu'elle comprend en outre une substance S2 permettant de diminuer l'évaporation desdits composés.2) Composition according to claim 1, characterized in that it further comprises a substance S2 for reducing the evaporation of said compounds.
3) Composition selon la revendication 1 ou 2, caractérisée en ce que la substance Sl et/ou la substance S2 comprend en outre des actifs agissant directement sur le stress.3) Composition according to claim 1 or 2, characterized in that the substance Sl and / or the substance S2 further comprises active acting directly on the stress.
4) Composition selon l'une quelconque des revendications 1 à 3, caractérisée en ce que les substances Sl et S2 sont de la phosphatidylsérine.4) Composition according to any one of claims 1 to 3, characterized in that the substances S1 and S2 are phosphatidylserine.
5) Composition selon la revendication 4, caractérisée en ce qu'elle comprend une quantité d'extrait de mélisse et de phosphatidylsérine permettant un apport journalier en une ou plusieurs prises de 50 à 500g de phosphatidylsérine et 100 à 1000 mg d'extrait de mélisse. 6) Composition selon la revendication 5, caractérisée en ce que la quantité d'extrait de mélisse et de phosphatidylsérine est choisie pour permettre un apport journalier en une ou plusieurs prises de 100 mg de phosphatidylsérine et 300 mg d'extrait de mélisse.5) Composition according to claim 4, characterized in that it comprises an amount of melissa extract and phosphatidylserine allowing a daily intake of one or more doses of 50 to 500g of phosphatidylserine and 100 to 1000 mg of melissa extract . 6) Composition according to claim 5, characterized in that the amount of melissa extract and phosphatidylserine is chosen to allow a daily intake of one or more doses of 100 mg of phosphatidylserine and 300 mg of lemon balm extract.
7) Composition selon l'une quelconque des revendications 1 à 6, caractérisée en ce que ledit extrait de mélisse est un extrait d'huile essentielle ou un extrait hydro-alcoolique.7) Composition according to any one of claims 1 to 6, characterized in that said melissa extract is an essential oil extract or a hydro-alcoholic extract.
8) Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle comprend en outre un ou plusieurs excipients pharmacologiques compatibles et adaptés au mode d'administration.8) Composition according to any one of the preceding claims, characterized in that it further comprises one or more pharmacological excipients compatible and adapted to the mode of administration.
9) Composition selon l'une quelconque des revendications précédentes, caractérisée en ce qu'elle se présente sous la forme de comprimé. 9) Composition according to any one of the preceding claims, characterized in that it is in the form of tablet.
PCT/FR2005/002463 2004-10-20 2005-10-06 Composition for preventing or treating stress, especially chronic and permanent bursts of stress WO2006042928A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0411155A FR2876586B1 (en) 2004-10-20 2004-10-20 COMPOSITION FOR PREVENTING OR TREATING STRESS, INCLUDING CHRONIC AND PERMANENT STRESS BURNS
FR0411155 2004-10-20

Publications (1)

Publication Number Publication Date
WO2006042928A1 true WO2006042928A1 (en) 2006-04-27

Family

ID=34950913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002463 WO2006042928A1 (en) 2004-10-20 2005-10-06 Composition for preventing or treating stress, especially chronic and permanent bursts of stress

Country Status (2)

Country Link
FR (1) FR2876586B1 (en)
WO (1) WO2006042928A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500040A (en) * 2007-10-17 2011-01-06 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Lemon balm extract-containing food composition
EP2881104A1 (en) * 2013-12-05 2015-06-10 Lonza Ltd Use of compositions comprising phosphatidylserine and phosphatidic acid and/or salts thereof for reducing or preventing sweating
WO2016118878A1 (en) * 2015-01-22 2016-07-28 Bob Fritz Phosphatidylserine-containing diet supplement aids with melatonin anti-catabolic dietary nutrients
US10017482B2 (en) 2004-10-19 2018-07-10 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617542A1 (en) * 1967-04-26 1971-04-08 Isnel Afife Dipl Chem Dr Process for the preparation of stable solutions of lecithin, especially soybean lecithin, in aqueous, sugary alcohol
US20010001307A1 (en) * 1998-02-23 2001-05-17 Taiyo Kagaku Co., Ltd. Composition comprising theanine
EP1116446A2 (en) * 1995-03-31 2001-07-18 Jörg-Peter Prof. Schür Method for improving shelf life and / or stability of products which may spoil by the influence of microbes
US20030104076A1 (en) * 2001-11-07 2003-06-05 Wilhelm Berkulin Process for preparing dry extracts
US20040009244A1 (en) * 2000-12-12 2004-01-15 Min-Young Kim Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617542A1 (en) * 1967-04-26 1971-04-08 Isnel Afife Dipl Chem Dr Process for the preparation of stable solutions of lecithin, especially soybean lecithin, in aqueous, sugary alcohol
EP1116446A2 (en) * 1995-03-31 2001-07-18 Jörg-Peter Prof. Schür Method for improving shelf life and / or stability of products which may spoil by the influence of microbes
US20010001307A1 (en) * 1998-02-23 2001-05-17 Taiyo Kagaku Co., Ltd. Composition comprising theanine
US20040009244A1 (en) * 2000-12-12 2004-01-15 Min-Young Kim Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
US20030104076A1 (en) * 2001-11-07 2003-06-05 Wilhelm Berkulin Process for preparing dry extracts

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LITTLE W ET AL: "Effects of Melissa officinalis (Lemon Balm) on mood changes during acute psychological stress.", JOURNAL OF PSYCHOPHARMACOLOGY, vol. 17, no. Supplement 3, September 2003 (2003-09-01), & SUMMER MEETING OF THE BRITISH ASSOCIATION FOR PSYCHOPHARMACOLOGY; CAMBRIDGE, ENGLAND, UK; JULY 20-23, 2003, pages A62, XP009046668, ISSN: 0269-8811 *
WEST I ET AL: "Contact urticaria syndrome from multiple cosmetic components.", CONTACT DERMATITIS. FEB 1995, vol. 32, no. 2, February 1995 (1995-02-01), pages 121, XP009046609, ISSN: 0105-1873 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10017482B2 (en) 2004-10-19 2018-07-10 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
JP2011500040A (en) * 2007-10-17 2011-01-06 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Lemon balm extract-containing food composition
JP2014121328A (en) * 2007-10-17 2014-07-03 Rudolf Wild Gmbh & Co Kg Food compositions comprising lemon balm extracts
US8993005B2 (en) 2007-10-17 2015-03-31 Rudolf Wild Gmbh & Co. Kg Food compositions comprising lemon balm extracts
EP2881104A1 (en) * 2013-12-05 2015-06-10 Lonza Ltd Use of compositions comprising phosphatidylserine and phosphatidic acid and/or salts thereof for reducing or preventing sweating
WO2015082682A1 (en) * 2013-12-05 2015-06-11 Lonza Ltd. Use of compositions comprising phosphatidylserine and phosphatidic acid and/or salts thereof for reducing or preventing sweating
WO2016118878A1 (en) * 2015-01-22 2016-07-28 Bob Fritz Phosphatidylserine-containing diet supplement aids with melatonin anti-catabolic dietary nutrients

Also Published As

Publication number Publication date
FR2876586A1 (en) 2006-04-21
FR2876586B1 (en) 2007-10-12

Similar Documents

Publication Publication Date Title
CA1125172A (en) Pharmaceutical composition and process for its preparation
JP2008110996A (en) Composition for reduction of body fat
CA3065135A1 (en) Compositions and methods to regulate hormonal cascades in stress disorders
US20120015021A1 (en) Anti-appetite adhesive compositions
WO2006042928A1 (en) Composition for preventing or treating stress, especially chronic and permanent bursts of stress
US20200138773A1 (en) Compositions and methods for enhancing sexual pleasure and performance
US20110038915A1 (en) Chewing Gum Formula for Enhancing Psycho-Spirituality
Sharma et al. Revisiting Licorice as a functional food in the management of neurological disorders: bench to trend
FR3080989A1 (en) LIQUID COMPOSITION COMPRISING AN EXTRACT OF CASSIS LEAVES AND CONCENTRATED APPLE JUICE
CA3151070A1 (en) Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids
AU2018436267A1 (en) Compositions and methods for treating sexual dysfunction and enhancing sexual response and pleasure
JP4325908B2 (en) Lipolysis accelerator, skin external preparation and food and drink using the same
US20120288450A1 (en) Chewing gum formula for enhancing psycho-spirituality
WO2021116203A1 (en) Composition of extract of dried stigmas of crocus sativus (saffron) and of flavonoid(s) for the treatment of severe allergic asthma
EP3624822B1 (en) Active agent comprising a mixture of poly-lysine compounds, and use in the treatment and prevention of post-stroke inflammation
JP2022543786A (en) Dietary supplement for use as an adjuvant for the prevention of vascular dementia
EP1971353A2 (en) Cosmetic compositions based on essential oils and use thereof in pain relief
FR3005263A1 (en) PHARMACEUTICAL OR DIETETIC COMPOSITION LIQUID OR SEMI-LIQUID FREE OF AMERTUME CONTAINING SALT OF ARGININE.
FR2931664A1 (en) PLANT COMPOSITIONS AND USES
EP2258354B1 (en) Compounds and methods for controlling alcohol intake
DE102004063363A1 (en) Composition for treatment and prevention of bronchial disease or allergy and for strengthening immune system, contains capsaicin or its derivatives
LU100019B1 (en) Composition for use in the treatment of psoriasis
FR2989557A1 (en) Composition, useful to eliminate psychological effects and physical and/or hormonal disorders related to premenstrual syndrome in girls or women, comprises minerals, vitamins and plant extracts e.g. extract of dried fruits of Chaste berry
FR2859108A1 (en) ANTI-STRESS COMPOSITION AND INHALER
FR3108036A1 (en) Pharmaceutical or dietetic composition containing the aqueous extract of lavender and usable as an antidiabetic

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05804196

Country of ref document: EP

Kind code of ref document: A1